Automate Your Wheel Strategy on VTRS
With Tiblio's Option Bot, you can configure your own wheel strategy including VTRS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VTRS
- Rev/Share 12.1281
- Book/Share 13.0668
- PB 0.8185
- Debt/Equity 1.0687
- CurrentRatio 1.3513
- ROIC -0.0782
- MktCap 12318178781.0
- FreeCF/Share 1.4143
- PFCF 7.4787
- PE -3.3743
- Debt/Assets 0.4289
- DivYield 0.0449
- ROE -0.2269
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | VTRS | Truist | -- | Buy | -- | $15 | Oct. 15, 2025 |
| Initiation | VTRS | Goldman | -- | Neutral | -- | $10 | June 6, 2025 |
News
What's in Store for These 5 Biotech Stocks This Earnings Season?
IOVA,
NTLA,
NVAX,
PRGO,
VTRS
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
Let's look at five biotech and drug companies, VTRS, PRGO, NVAX, NTLA and IOVA, slated to release their fourth-quarter 2024 results on Feb. 27, 2025.
Read More
What's in the Cards for Viatris Stock This Q4 Earnings?
VTRS
Published: February 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: February 21, 2025 by: Zacks Investment Research
Sentiment: Positive
VTRS' Q4 results are likely to gain from new product launches in all major geographies.
Read More
About Viatris Inc. (VTRS)
- IPO Date 1980-03-17
- Website https://www.viatris.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Scott Andrew Smith
- Employees 32000
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.